...
首页> 外文期刊>Clinical Chemistry >Standardization of High-Sensitivity Immunoassays for Measurement of C-Reactive Protein; II: Two Approaches for Assessing Commutability of a Reference Material
【24h】

Standardization of High-Sensitivity Immunoassays for Measurement of C-Reactive Protein; II: Two Approaches for Assessing Commutability of a Reference Material

机译:用于测量C反应蛋白的高灵敏度免疫测定的标准化; II:评估参考物质可交换性的两种方法

获取原文
获取原文并翻译 | 示例

摘要

We evaluated the commutability of a proposed reference material (PRM), with a formulation based on dilution of Certified Reference Material 470 (CRM470), for 24 high-sensitivity C-reactive protein (hsCRP) methods. We also investigated whether calibration by use of PRM was effective in harmonizing results. A set of 40 native clinical samples was measured along with PRM and 3 dilutions of PRM. We used weighted least-squares polynomial regression (WLS/PR) to perform comparisons between all method combinations and to calculate normalized residuals for the PRM. The PRM was considered non-commutable if any of the normalized residuals for a method pair was >2. Correspondence analysis (CA) was used to explore the multidimensional relationships between methods and samples to evaluate if the PRM had properties similar to native clinical samples. Clinical sample results from the methods for which PRM was commutable were recalibrated based on the PRM results, and ANOVA was used to estimate the CVs before and after recalibration. After omitting data for 9 methods because of poor precision or procedural flaws, we used data from the 15 remaining methods to evaluate commutability. Using both WLS/PR and CA we found that PRM was noncommutable with 1 method. We found modest improvement in total and among-method CVs when PRM was used to harmonize the results from the 14 methods for which it was commutable. A PRM with a formulation based on dilution of CRM470 was commutable with native clinical samples for 14 of 15 hsCRP methods that had acceptable precision. For those methods the use of PRM may contribute to improved harmonization of results for native clinical samples.
机译:我们使用24种高灵敏度C反应蛋白(hsCRP)方法,以基于认证参考物质470(CRM470)稀释的配方评估了拟议参考物质(PRM)的可交​​换性。我们还调查了通过使用PRM进行校准是否有效地协调了结果。测量了一组40个天然临床样品以及PRM和3个PRM稀释液。我们使用加权最小二乘多项式回归(WLS / PR)在所有方法组合之间进行比较并计算PRM的归一化残差。如果方法对的任何归一化残差均大于2,则认为PRM是不可交换的。对应分析(CA)用于探索方法与样品之间的多维关系,以评估PRM是否具有与天然临床样品相似的特性。根据PRM结果对来自可交换PRM的方法的临床样品结果进行重新校准,并使用ANOVA估计重新校准前后的CV。由于精度低或程序缺陷而省略了9种方法的数据后,我们使用了其余15种方法的数据来评估可交换性。同时使用WLS / PR和CA,我们发现PRM无法通过1种方法交换。当使用PRM协调可互换的14种方法的结果时,我们发现CV的总体和方法间的适度改进。在15 hsCRP方法中,有14种具有基于CRM470稀释度的配方的PRM可与天然临床样品进行交换,且该方法具有可接受的精度。对于那些方法,使用PRM可能有助于改善天然临床样品结果的一致性。

著录项

  • 来源
    《Clinical Chemistry 》 |2009年第2期| p.342-350| 共9页
  • 作者单位

    Mary M. Kimberly,1* Samuel P. Caudill,1 Hubert W. Vesper,1 Elizabeth A. Monsell,1 W. Greg Miller,2 Robert Rej,3 Nader Rifai,4 Francesco Dati,5 and Gary L. Myers11 Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, 2 Medical College of Virginia Hospitals at Virginia Commonwealth University, Richmond, VA, 3 Wadsworth Center for Laboratories and Research, New York State Department of Health, Albany, NY, 4 Departments of Laboratory Medicine and Pathology, Children's Hospital and Harvard Medical School, Boston, MA, 5 IVD Consulting, Marburg, Germany.* Address correspondence to this author at: Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Mailstop F25, 4770 Buford Hwy NE, Atlanta, GA 30341-3724. Fax (770) 488-7030, e-mail mkimberly@cdc.gov.Received November 4, 2008, accepted November 15, 2008.Previously published online at DOI: 10.1373/clinchem.2008.115907Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data, (b) drafting or revising the article for intellectual content, and (c) final approval of the published article.Authors' Disclosures of Potential Conflicts of Interest: Upon manuscript submission, all authors completed the Disclosures of Potential Conflict of Interest form. Potential conflicts of interest:Employment or Leadership: G. Miller, AACC and CLSI.Consultant or Advisory Role: F.A. Dati, Myconostica, Manchester, UK, and General Biologicals, Taiwan.Stock Ownership: None declared.Honoraria: None declared.Research Funding: None declared.Expert Testimony: None declared.Other Remuneration: F.A. Dati, DiaSys, Shanghai, China.Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, preparation or approval of manuscript.Acknowledgments: The authors thank the following people and companies who participated in this study: Chester Swirski (Bayer Diagnostics, Tarrytown, NY), Daniel B. Seymour (Beckman Coulter, Brea, CA), Josep Serra (Biokit SA, Barcelona, Spain), Neal Bellet (Cholestech, Hayward, CA), Lone Juhl (DakoCytomation, Glostrup, Denmark), Manfred Lammers (Dade Behring Marburg, Marburg, Germany), Kazunori Saito (Daiichi Pure Chemicals, Ibaraki, Japan), Yousuke Meguro (Denka Seiken, Niigata, Japan), Erwin Metzmann (DiaSys Diagnostic Systems, Holzheim, Germany), Hideyuki Hayashi (Eiken Chemical, Tochigi, Japan), Katherine Ekholm (Genzyme Diagnostics, Cambridge, MA), Victor Chiou (Good Biotech, Taichung City, Taiwan, R.O.C.), Et-suko Sato (Iatron Laboratories, Chiba, Japan), Virpi Leppänen (Innotrac Diagnostics Oy, Turku, Finland), Ikuo Terunuma (Nissui Pharmaceutical, Ibaraki, Japan), Ryo Kojima (Nitto Boseki, Koriyama, Japan), Matthew D. McCusker (Olympus Diagnostica Ireland, County Clare, Ireland), Anja Taulaniemi (Orion Diagnostica, Espoo, Finland), Ron Jamison (Pointe Scientific, Canton, Michigan), Günter Trefz (Roche Diagnostics, Penzberg, Germany), and David Li (Wako Diagnostics, Richmond, VA).,;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号